CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
Nivolumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02631746
NCT02631746Phase 2Completed
CompareCT.gov

Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma

National Cancer Institute (NCI)·interventional·Posted Dec 16, 2015·Updated Mar 14, 2025

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Nivolumab, and 1 other intervention for Acute Adult T-Cell Leukemia/Lymphoma and 5 related conditions. Completed, enrolled 3 participants across 6 sites.

Detailed Summary

This phase II trial studies how well nivolumab works in treating patients with human T-cell leukemia virus (HTLV)-associated T-cell leukemia/lymphoma. Nivolumab is an antibody, which is a type of blood protein that tags infected cells and other harmful agents. Nivolumab works against a protein called programmed cell death (PD)-1 and may help the body destroy cancer cells by helping the immune system to keep fighting cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection, Lymphomatous Adult T-Cell Leukemia/Lymphoma, Smoldering Adult T-Cell Leukemia/Lymphoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 16, 2015
Enrollment StartFeb 23, 2017
Primary CompletionMar 30, 2018
Study CompletionJul 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.5 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Nivolumabbiological

Given IV

Pharmacogenomic Studyother

Correlative studies